Coherus BioSciences, inc (CHRS) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Cytokinetics, Incorporated (CYTK) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics First Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company s request, we will open the call for questions-and-answers after the presentation.
I will now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Senior Vice President of Corporate Communications & Investor Relations
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including progress following a recent meeting with FDA and what to expect from upcoming analyses from GALACTIC-H
Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
Cytokinetics Inc (NASDAQ: CYTK)
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Fourth Quarter 2020 Conference Call. [Operator Instructions]
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Creations and Investor Relations. Please go ahead.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company s SEC filings. Please see our